DERMABOND® Portfolio
Value Proposition

The third party trademarks used herein are trademarks of their respective owners.
Wound closure success is key to a great surgical outcome

Choosing the **right** topical skin adhesive (TSA) can provide a host of wound healing benefits:

- ✓ Strength and security throughout the healing process\(^1,2\)
- ✓ Microbial barrier protection\(^3\)
- ✓ Patient satisfaction benefits\(^1,4\)
- ✓ Excellent cosmesis\(^5\)

References
4. DERMABOND® PRINEO® Skin Closure System, Instructions for Use. Ethicon, Inc.
Don’t compromise
Choose the only topical skin adhesive (TSA) that has been tried, tested, and trusted for nearly 20 years.
Supported by more clinical evidence than the top six competitors combined

DERMABOND ADVANCED® Topical Skin Adhesive is supported by substantially more randomized controlled trials (RCTs) than the top 6 competitors combined.¹⁻³*†‡

DERMABOND ADVANCED Adhesive²*
5,718 patients

Top six competitors combined³†‡
612 patients

---

*DERMABOND ADVANCED Adhesive tests equivalent or superior to DERMABOND Adhesive in head-to-head testing for microbial barrier, wound-bursting strength, tensile strength, flexibility, durability, viscosity, drying time, water vapor transmission rate, water resistance, and physician satisfaction.

†Based on published literature in PubMed as of March 7, 2017, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.

‡Top 6 US competitors include LiquiBand®, Skin Aix™, SwiftSet™, SurgiSeal®, DermaFlex® QS™, and Histoacryl®.

Large retrospective analyses support the clinical and economic benefits of DERMABOND ADVANCED® Topical Skin Adhesive

In a retrospective study of 1,360 patients in CABG surgery, postoperative hospital stay was reduced from 13 to 9 days when DERMABOND ADVANCED Adhesive was used in addition to conventional sutures\(^1\)

In a retrospective database study of 155,557 C-sections, hospitalization costs were $500 lower for the DERMABOND ADVANCED Adhesive skin closure group vs. staples or sutures alone\(^2\)*

*Premier Perspective™ Comparative Database

Sustained innovation has given rise to the only brand that offers a complete portfolio of skin closure solutions for a wide variety of incision length and closure strength needs.
**DERMABOND® Portfolio of topical skin adhesives – a comprehensive portfolio for a variety of clinical needs**

### Strength and protection

<table>
<thead>
<tr>
<th>Ideal for:</th>
<th>DERMABOND® Mini Topical Skin Adhesive</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Small lacerations</td>
<td></td>
</tr>
<tr>
<td>• Minimally invasive procedures</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ideal for:</th>
<th>DERMABOND ADVANCED® Topical Skin Adhesive</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Open hernia repair</td>
<td></td>
</tr>
<tr>
<td>• Mid to large lacerations</td>
<td></td>
</tr>
</tbody>
</table>

*Equivalent to a 4-0 MONOCRYL® (poliglecaprone 25) Suture.

### Uncompromised strength and protection for excellent wound closure security

<table>
<thead>
<tr>
<th>Ideal for:</th>
<th>DERMABOND® PRINEO® Skin Closure System (22 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Orthopedic surgeries:</td>
<td></td>
</tr>
<tr>
<td>– Total knee arthroplasty</td>
<td></td>
</tr>
<tr>
<td>– Total hip arthroplasty</td>
<td></td>
</tr>
<tr>
<td>– Spine surgeries</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ideal for:</th>
<th>DERMABOND® PRINEO® Skin Closure System (42 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Sternotomy</td>
<td></td>
</tr>
<tr>
<td>• Spine deformities</td>
<td></td>
</tr>
<tr>
<td>• Open laparotomy</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ideal for:</th>
<th>DERMABOND® PRINEO® Skin Closure System (60 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Abdominoplasty</td>
<td></td>
</tr>
<tr>
<td>• Breast reconstruction</td>
<td></td>
</tr>
<tr>
<td>• Brachioplasty</td>
<td></td>
</tr>
</tbody>
</table>

*Equivalent to a 3-0 MONOCRYL Suture.

---

### References
DERMABOND® PRINEO® Skin Closure System
Beyond sutures and staples lies a more innovative solution

Powerful combination of 2-octyl cyanoacrylate (2-OCA) and self-adhering mesh

DERMABOND PRINEO System (22 cm)
DERMABOND PRINEO System (42 cm)
DERMABOND PRINEO System (60 cm)
Designed to promote an ideal wound-healing environment

**Protection**
- Provides microbial-barrier protection 99% effective in vitro for 72 hours against organisms commonly responsible for surgical site infection (SSI)\(^*\)
  - Demonstrates in vitro inhibition of bacteria (Methicillin-resistant *Staphylococcus aureus*, Methicillin-resistant *Staphylococcus epidermidis*, *Escherichia coli*)\(^\dagger\)

**Strength**
- Significantly greater skin holding strength than skin staples or subcuticular suture\(^3,4\dagger\)
- Redistributes tension away from the wound to the surrounding healthy surface area

**Patient Satisfaction**
- Patient may be able to shower immediately after the procedure, if directed by the healthcare professional\(^5\)
- At the time of removal, DERMABOND PRINEO System is associated with less pain than other wound closure devices\(^6\)
- No post-surgical dressings may mean easier self-care and greater self-confidence for patients\(^7\)
- Leads to better cosmesis and greater overall patient satisfaction compared to staples\(^8\dagger\)

\(^*\) *Staphylococcus epidermidis*, *Escherichia coli*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Enterococcus faecium*.
\(^\dagger\) Clinical significance unknown.
\(^\dagger\) In an ex vivo study, more load in N was required to create a 3-mm gap between skin edges approximated with DERMABOND PRINEO System (22 cm) than with subcuticular 4-0 MONOCRYL® (poliglecaprone 25) Suture or PROXIMATE® Ethicon Endo-Surgery skin staples (P<.001).
\(^\dagger\) Double-blinded quantitative research study comparing surgeon experience with DERMABOND PRINEO System and skin staples in total knee arthroplasty. N=83 Orthopaedic surgeons. 90% CI. Fielded June/July 2017.

**References:**
Cosmesis and patient satisfaction

A double-blinded quantitative research study of surgeon and patient experience with DERMABOND® PRINEO® Skin Closure System compared to skin staples in total knee arthroplasty was conducted in June and July of 2017 and found:

**Cosmesis**
- DERMABOND PRINEO System leads to **better cosmesis** compared to staples
- Surgeons agreed that patients with DERMABOND PRINEO System were **happier with cosmetic outcomes**
- Patients closed with DERMABOND PRINEO System were **more satisfied with appearance** of knee incision compared to skin staples

**Patient satisfaction**
- DERMABOND PRINEO System leads to **greater overall patient satisfaction** compared to staples
- Patients agreed that DERMABOND PRINEO System incisions require **less special care and attention** than incisions with staples
- Surgeons agreed that DERMABOND PRINEO System resulted in **less wound drainage** compared to staples
- Patients were **more comfortable** with DERMABOND PRINEO System incision post-surgery

**Surgeon satisfaction**
- Surgeons agreed they **worry less** about patients with DERMABOND PRINEO System taking care of incisions at home compared to patients with staples
- Surgeons agreed that DERMABOND PRINEO System **reduced unscheduled office visits and calls** compared to staples
- Surgeons agreed that DERMABOND PRINEO System **saves personal time** due to less postoperative incision issues compared to skin staples


*83 interviews among Orthopaedic surgeons using both DERMABOND PRINEO System and staples; 88 interviews were conducted among patients (50 skin staples; 38 DERMABOND PRINEO System) who recently had total knee replacement surgery.
Superior strength compared to skin staples or 4-0 suture

**DERMABOND® PRINEO® Skin Closure System (22 cm) was shown to be:**\(^1,2\)*

<table>
<thead>
<tr>
<th>Strength Comparison</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stronger than staples on average</td>
<td>33%</td>
</tr>
<tr>
<td>Stronger than 4-0 suture on average</td>
<td>40%</td>
</tr>
</tbody>
</table>

*Study performed ex vivo.

Uniform distribution of tension

Visual maps of tension across the incisions revealed that incisions closed with DERMABOND® PRINEO® Skin Closure System (22 cm) had a more uniform distribution of tension¹*

*Mapped strains in DERMABOND® PRINEO® Skin Closure System 22 cm (DP22) Comparative Study

**DERMABOND® PRINEO® Skin Closure System**

**Total Knee Arthroplasty—Retrospective Study Results**

DERMABOND PRINEO System is associated with statistically significant reduced length of stay, reduced probability of discharge to SNF* or other non-home setting, and reduced readmission rates when compared to skin staples\(^1\)

### 30-60-90-DAY ALL-CAUSE READMISSION RATES\(^1\)

<table>
<thead>
<tr>
<th></th>
<th>Skin Staples</th>
<th>DERMABOND PRINEO System</th>
</tr>
</thead>
<tbody>
<tr>
<td>30-Day</td>
<td>4.4%</td>
<td>1.8%</td>
</tr>
<tr>
<td>60-Day</td>
<td>5.4%</td>
<td>3.0%</td>
</tr>
<tr>
<td>90-Day</td>
<td>7.4%</td>
<td>5.4%</td>
</tr>
</tbody>
</table>

$12,839^2$ Potential cost savings by avoiding readmission within 30 days TKA

12% reduction in length of stay

With DERMABOND PRINEO System\(^1\)

31% reduction in discharge to non-home setting

With DERMABOND PRINEO System\(^1\)

---

*SNF= Skilled nursing facility

References
An economic model demonstrates the resource savings potential of DERMABOND® PRINEO® Skin Closure System

In hip and knee arthroplasty, decreases in resource utilization in the post-acute care setting may lead to the following:

- Hospital budgetary savings ranging from $28,349 to $39,809
  
- Cost savings of $56.70 to $79.62 per patient

*Assuming 500 hip and knee arthroplasties when standard or premium dressings are used, respectively, with sutures or staples.
†In a 90-day economic model where DERMABOND PRINEO System is used in 60% of cases, sutures in 20% of cases, skin staples in 20% of cases.
‡When standard or premium dressings are used, respectively, with sutures or staples.

Addressing risk factors associated with surgical site infection (SSI)

In healthcare today, reimbursement and reporting policies are placing increased pressure on hospitals to avoid SSI.

DERMABOND ADVANCED® Topical Skin Adhesive and DERMABOND® PRINEO® Skin Closure System are proven 99% effective through 72 hours in vitro against organisms commonly responsible for SSIs, including:\(^1,^2\)

- *Staphylococcus epidermidis*
- *Staphylococcus aureus*
- *Escherichia coli*
- *Pseudomonas aeruginosa*
- *Enterococcus faecium*

Wound closure is key to a great surgical outcome

Don’t settle for less than the innovation, efficacy, and evidence behind the DERMABOND® Portfolio
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.